PR PolyResearch

Join Free

NASDAQ

MacroGenics, Inc. (MGNX)

♥ 559 Thanks from members

MacroGenics, Inc. (MGNX) exhibits a cautiously optimistic net web sentiment, buoyed by a refocused next-generation antibody-drug conjugate (ADC) pipeline, extended cash runway through 2027-2028 from partnership proceeds, and high-stakes 2026 clinical data catalysts.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other Nasdaq Tickers

GraniteShares 2x Long AAPL Daily ETF (AAPB)

Apple Inc. (AAPL)

Direxion Daily AAPL Bear 1X ETF (AAPD)

Ascentage Pharma Group International - American Depository Shares (AAPG)

Direxion Daily AAPL Bull 2X ETF (AAPU)

Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)